Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details)

v3.20.2
Commitments and Contingencies (Details)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 24, 2020
USD ($)
Feb. 24, 2020
CNY (¥)
Aug. 29, 2019
USD ($)
Oct. 23, 2018
USD ($)
May 29, 2018
Oct. 25, 2017
Sep. 30, 2020
USD ($)
Sep. 30, 2020
USD ($)
Dec. 31, 2019
USD ($)
Oct. 23, 2018
CNY (¥)
Commitments and Contingencies (Details) [Line Items]                    
Stock purchase agreement, description           Beijing Genexosome and Yu Zhou, MD, PhD, the sole shareholder of Beijing Genexosome, pursuant to which Genexosome acquired all of the issued and outstanding securities of Beijing Genexosome in consideration of a cash payment in the amount of $450,000, of which $100,000 is still owed. Further, on October 25, 2017, Genexosome entered into and closed an Asset Purchase Agreement with Dr. Zhou, pursuant to which the Company acquired all assets, including all intellectual property and exosome separation systems, held by Dr. Zhou pertaining to the business of researching, developing and commercializing exosome technologies. In consideration of the assets, Genexosome paid Dr. Zhou $876,087 in cash, transferred 500,000 shares of common stock of the Company to Dr. Zhou and issued Dr. Zhou 400 shares of common stock of Genexosome.        
Lease, description The term of the Beijing Office Lease is 12 months commencing on March 1, 2020 and expires on February 28, 2021. The term of the Beijing Office Lease is 12 months commencing on March 1, 2020 and expires on February 28, 2021.                
Joint venture agreement, description       Within 6 days of signing the AVAR Agreement, Avactis is required to pay to Arbele $300,000 as a research and development fee with an additional two payments of $300,000 (for a total of $900,000) to be paid upon mutually agreed upon milestones.            
Line of Credit Agreement [Member]                    
Commitments and Contingencies (Details) [Line Items]                    
Line of credit     $ 20,000,000              
Line of Credit bears interest at an annual rate     5.00%              
Received Loan               $ 2,900,000    
Avalon Shanghai [Member]                    
Commitments and Contingencies (Details) [Line Items]                    
Joint venture agreement, description         Avalon Shanghai entered into a Joint Venture Agreement with Jiangsu Unicorn Biological Technology Co., Ltd. (“Unicorn”), pursuant to which a company named Epicon Biotech Co., Ltd. (“Epicon”) was formed on August 14, 2018. Epicon is owned 60% by Unicorn and 40% by Avalon Shanghai. Within five years of execution of the Joint Venture Agreement, Unicorn shall invest cash into Epicon in an amount not less than RMB 8,000,000 (approximately $1.2 million) and the premises of the laboratories of Nanjing Hospital of Chinese Medicine for exclusive use by Epicon, and Avalon Shanghai shall invest cash into Epicon in an amount not less than RMB 10,000,000 (approximately $1.5 million). Epicon is focused on cell preparation, third party testing, biological sample repository for commercial and scientific research purposes and the clinical transformation of scientific achievements. As of September 30, 2020, Avalon Shanghai has contributed RMB 4,300,000 (approximately $0.6 million) that was included in equity method investment on the accompanying consolidated balance sheets          
AVAR BioTherapeutics (China) Co. Ltd. [Member]                    
Commitments and Contingencies (Details) [Line Items]                    
Joint venture agreement, description       Avactis Biosciences, Inc. (“Avactis”), a wholly-owned subsidiary of the Company, and Arbele Limited (“Arbele”) agreed to the establishment of AVAR BioTherapeutics (China) Co. Ltd. (“AVAR”), a Sino-foreign equity joint venture, pursuant to an Equity Joint Venture Agreement (the “AVAR Agreement”), which will be owned 60% by Avactis and 40% by Arbele. The purpose and business scope of the Joint Venture is to research, develop, produce, sell, distribute and generally commercialize CAR-T/CAR-NK/TCR-T/universal cellular immunotherapy in China. Avactis is required to contribute $10 million (or equivalent in RMB) in cash and/or services, which shall be contributed in tranches based on milestones to be determined jointly by AVAR and Avactis in writing subject to Avactis’ cash reserves. Within 30 days, Arbele shall make a contribution of $6.66 million in the form of entering into a License Agreement with AVAR granting AVAR with an exclusive right and license in China to its technology and intellectual property pertaining to CAR-T/CAR-NK/TCR-T/universal cellular immunotherapy technology and any additional technology developed in the future with terms and conditions to be mutually agreed upon Avactis and AVAR and services.            
Working capital       $ 700,000           ¥ 5,000,000
Research and development expense               900,000    
Avalon Shanghai Office Lease [Member]                    
Commitments and Contingencies (Details) [Line Items]                    
Lease, monthly rent $ 7,000 ¥ 50,586                
Security deposit 24,000 164,764                
Operating lease maintenance fees $ 600 ¥ 4,336                
Rent expense             $ 36,000 67,000    
Operating lease               40,438    
New York Lease [Member]                    
Commitments and Contingencies (Details) [Line Items]                    
Lease, monthly rent                 $ 6,000  
Lease, description                 The term of the New York Lease is 3 years commencing on January 1, 2020 and expires on December 31, 2022.  
Rent expense             $ 18,000 $ 54,000